

Claims:

1. An ophthalmic pharmaceutical composition useful in the treatment of glaucoma or ocular hypertension comprising an effective amount of brimonidine and an effective amount of timolol in a pharmaceutically acceptable carrier therefor.
5
2. A composition according to Claim 1, wherein the concentration of brimonidine is 0.01 to 0.5 percent by weight and the concentration of timolol is 0.1 to 1.0 percent by weight.
10
3. A composition according to Claim 1, wherein the concentration of brimonidine is 0.2 percent by weight and the concentration of the timolol is 0.5 percent by weight.
4. A composition according to claim 1 further comprising from 0.001% to less than 0.01% benzalkonium chloride.
15
5. A composition according to claim 2 further comprising from 0.001% to less than 0.01% benzalkonium chloride.
20
6. A composition according to claim 3 further comprising from 0.001% to less than 0.01% benzalkonium chloride.
7. A method of treating glaucoma which comprises administering a therapeutically effective amount of a composition according to Claim 1 topically to the affected eye.
25

8. A method of treating glaucoma which comprises administering a therapeutically effective amount of a composition according to Claim 2 topically to the affected eye.

5 9. A method of treating glaucoma which comprises administering a therapeutically effective amount of a composition according to Claim 3 topically to the affected eye.

10 10. A method of lowering intraocular pressure which comprises administering a therapeutically effective amount of a composition according to Claim 1 to the affected eye.

15 11. A method of lowering intraocular pressure which comprises administering a therapeutically effective amount of a composition according to Claim 2 to the affected eye.

20 12. A method of lowering intraocular pressure which comprises administering a therapeutically effective amount of a composition according to Claim 3 to the affected eye.

25 13. An article of manufacture comprising packaging material and a pharmaceutical agent contained within said packaging material, wherein the pharmaceutical agent is therapeutically effective for lowering intraocular pressure and wherein the packaging material comprises a label which indicates the pharmaceutical agent can be used for lowering intraocular pressure and wherein said pharmaceutical agent comprises effective amount of brimonidine and an effective amount of timolol.

14. An article of manufacture according to claim 13 wherein said effective amount of brimonidine is from 0.01 to 0.5 percent by weight and said effective amount of timolol is from 0.1 to 1.0 percent by weight.

5 15. An article of manufacture according to claim 13 wherein said effective amount of brimonidine is 0.2 percent by weight and said effective amount of timolol is 0.5 percent by weight.

16. An article of manufacture according to claim 13 wherein said
10 pharmaceutical agent further comprises from 0.001% to less than 0.01% benzalkonium chloride.

17. An article of manufacture according to claim 16 further comprising
0.005% benzalkonium chloride.

15

18. An article of manufacture according to claim 14 further comprising
0.005% benzalkonium chloride.

19. An article of manufacture according to claim 15 further comprising
20 0.005% benzalkonium chloride.

20. A method of treating glaucoma which comprises administering a
therapeutically effective amount of a composition according to Claim 4 topically to
the affected eye.

25

21. A method of treating glaucoma which comprises administering a
therapeutically effective amount of a composition according to Claim 5 topically to
the affected eye.

22. A method of treating glaucoma which comprises administering a therapeutically effective amount of a composition according to Claim 6 topically to the affected eye.

5 23. A method of lowering intraocular pressure which comprises administering a therapeutically effective amount of a composition according to Claim 4 to the affected eye.

24. A method of lowering intraocular pressure which comprises
10 administering a therapeutically effective amount of a composition according to Claim 5 to the affected eye.

25. A method of lowering intraocular pressure which comprises
administering a therapeutically effective amount of a composition according to
15 Claim 6 to the affected eye.